What weekly dose of insulin icodec should be given to an adult with type 2 diabetes who is currently on insulin glargine 36 units per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Insulin Icodec Dose Calculation from Glargine 36 Units Daily

For a patient taking insulin glargine 36 units per day, the initial weekly insulin icodec dose should be 378 units (36 units × 7 × 1.5), rounded to 380 units, which includes a mandatory 50% one-time additional loading dose for the first injection only. 1

Dosing Algorithm for Switching from Daily Basal Insulin to Icodec

First Injection (Week 1)

  • Calculate base weekly dose: Daily glargine dose × 7 = 36 × 7 = 252 units
  • Add 50% loading dose: 252 × 1.5 = 378 units
  • Round to nearest 10 units: 380 units for first injection 1

The 50% one-time additional dose is recommended when switching from daily basal insulin to prevent transient hyperglycemia during the 2-4 weeks needed to reach steady state 1. This loading dose approach reduces fasting plasma glucose elevation and time above range in the first 4 weeks compared to initiating without additional dosing 1.

Second Injection Onward (Week 2+)

  • Use base weekly dose only: 36 × 7 = 252 units, rounded to 250 units
  • No additional loading dose after first injection 1

The icodec pen adjusts in 10-unit increments, so all doses should be rounded to the nearest 10 units 1.

Important Clinical Considerations

Monitoring Requirements

  • Measure prebreakfast self-monitored blood glucose (SMBG) three times weekly: 2 days prior to and on the day of each weekly injection 1
  • Continuous glucose monitoring (CGM) is strongly recommended during the initial transition period to detect both hyperglycemia and hypoglycemia 1
  • Increase monitoring frequency during the first 2-4 weeks as steady state is achieved 1

Titration After Initiation

Weekly dose adjustments should be based on the three prebreakfast SMBG values:

  • If any value is below target range: Titrate based on the lowest recorded value
  • If all values are above target range: Titrate based on the mean of the three measurements
  • Target prebreakfast glucose: 80-130 mg/dL (4.4-7.2 mmol/L) 1

Special Population Adjustments

For this specific patient on 36 units daily, no dose reduction is typically needed unless:

  • Low BMI or chronic kidney disease: Consider starting at 50% of calculated dose (approximately 180-190 units for first injection) 1
  • Elderly patients or those with hepatic/renal impairment: May titrate less aggressively but can use standard starting dose 1
  • History of severe hypoglycemia or hypoglycemia unawareness: Exercise caution and consider more conservative dosing 1

Hypoglycemia Risk

The ONWARDS 2 trial, which specifically studied patients switching from daily basal insulin (similar to this clinical scenario), showed comparable hypoglycemia rates between icodec and degludec 1. However, the 50% loading dose does not increase hypoglycemia risk compared to the base dose alone 1. Clinical steady state is reached 2-3 weeks after initiation with the loading dose versus 2-4 weeks without it 1.

Concomitant Medications

  • Continue other non-insulin glucose-lowering medications
  • Reduce or discontinue insulin secretagogues (sulfonylureas, meglitinides) to minimize hypoglycemia risk 1
  • No dose adjustment needed for renal or hepatic impairment per FDA labeling 2

Key Pitfalls to Avoid

  1. Do not repeat the 50% loading dose: Only the first injection receives the additional dose; subsequent injections use the base weekly calculation 1
  2. Do not underdose: The full 1.5× multiplier for week 1 is important to prevent transient hyperglycemia during the loading phase 1
  3. Ensure proper patient education: Clear instructions are critical to prevent accidental overdosing or confusion about the one-time loading dose 1
  4. Do not mix or dilute: Icodec must be administered alone, not mixed with other insulins 2

Related Questions

What is the recommended approach to initiating once‑weekly basal insulin (insulin icodec) in a patient with type 2 diabetes who requires basal insulin but prefers fewer injections?
How should a patient on Mixtard (biphasic insulin aspart 30/70) 36 U in the morning and 24 U in the evening be switched to a weekly insulin icodec regimen, including initial and maintenance doses?
How should Awiqli (insulin icodec) be initiated and titrated in an adult with type 1 or type 2 diabetes requiring basal insulin?
What is the appropriate dosing regimen for initiating weekly insulin icodec in an adult (≥18 years) with type 2 diabetes who is insulin‑naïve?
What initial dose of Lantus (insulin glargine) should be prescribed for a 60-year-old male with type 2 diabetes and an A1c of 9.9% who is medication‑naïve?
What sexual side effects can occur with oral minoxidil and how should they be managed?
What are the recommended dosing, monitoring, adverse effects, and alternative treatment options for tafacitinib in inflammatory bowel disease such as ulcerative colitis and Crohn’s disease?
What is the appropriate indication, dosage, contraindications, and monitoring for ferrous sulfate therapy in adults?
What is the recommended follow‑up schedule and management after adrenalectomy, including timing of visits, laboratory tests, and steroid replacement guidelines?
In a 67-year-old male with incidentally discovered hepatic lesions on CT urogram, do the lesions require further evaluation?
How should a patient on Mixtard (biphasic insulin aspart 30/70) 36 U in the morning and 24 U in the evening be switched to a weekly insulin icodec regimen, including initial and maintenance doses?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.